Neurocrine Biosciences | NBIX - Debt


Neurocrine Biosciences reported $406.2M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
ALKERMES USD 1.58B 1.51B Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amgen USD 57.32B 2.72B Mar/2026
Biogen USD 8.09B 1.53B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Cytokinetics USD 1.29B 4.48M Mar/2026
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Exelixis USD 169.54M 3.5M Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Pfizer USD 63.73B 231M Mar/2026
Prothena USD 7.65M 1.43M Mar/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Repligen USD 690.94M 144.36M Jun/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Teva Pharmaceutical Industries USD 16.91B 187M Mar/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026